領益智造(002600.SZ):海南領益與上海子緒共同投資設立領卓科技(海南)有限公司
格隆匯12月6日丨領益智造(002600.SZ)公佈,因發展戰略的需要,充分藉助專業投資機構的產業資源及產業投資管理優勢,以提升公司核心競爭力和盈利能力,公司全資子公司海南領益與上海子緒共同投資設立領卓科技(海南)有限公司,註冊資本為1000萬元人民幣,海南領益以自有資金認繳出資800萬元人民幣,出資比例為80%。
領卓科技(海南)有限公司經營範圍:一般項目技術服務、技術開發、技術諮詢、技術交流、技術轉讓、技術推廣;信息技術諮詢服務;信息諮詢服務。
股權結構:海南領益持有領卓科技(海南)有限公司80%股權,上海子緒持有領卓科技(海南)有限公司20%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.